• Marc Marti-Pastor, Ricardo Bou-Monterde, Lucia Ciancotti-Oliver, Marta Alcover-Pons, Aurora Amorós Cantero, Raquel Sánchez-Lopezosa, and Neus Montañana-Rosell.
• Servicio de Medicina Preventiva y Salud Pública. Hospital Universitario de la Ribera, Valencia, España. Electronic address: mmartip27@gmail.com.
• Med Clin (Barc). 2024 Sep 27; 163 (6): 275280275-280.

IntroductionInmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients.Materials And Methods119 immunocompromised people>18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld. Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2. Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package.ResultsIn total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI=0.09-0.90) for SARS-CoV-2 infection, 0.37 (0.07-1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03-2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group.ConclusionsThis study demonstrates that Evusheld reduces the SARS-CoV-2 infections.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

30 keywords...

hide…